首页 > 最新文献

Parkinsonism & related disorders最新文献

英文 中文
Functional movement disorders in dopa-responsive dystonia
IF 3.1 3区 医学 Q2 CLINICAL NEUROLOGY
Parkinsonism & related disorders
Pub Date : 2025-01-19 DOI: 10.1016/j.parkreldis.2025.107292
Feline Hamami , Jannik Prasuhn , Leon-Claas van Well , Katja Lohmann , Christine Klein , Norbert Brüggemann , Tobias Bäumer , Alexander Münchau , Anne Weissbach

Background

Functional neurological movement disorders are common and disabling. Little is known about their coexistence with other non-functional movement disorders and their impact on the general disease burden.

Objectives

Investigating frequency and characteristics of functional movement disorders in GCH1-positive dopa-responsive dystonia patients.

Methods

Twenty-one patients underwent a detailed clinical motor examination and completed self-questionnaires evaluating non-motor characteristics.

Results

Seven patients (33 %) had comorbid functional movement symptoms, including functional gait disorders (n = 7), balance disturbances (n = 7), and weakness (n = 5), dominating the clinical phenotype and resulting in disability with immobilization. None of them was previously diagnosed with or treated for the functional symptoms. Functional movement symptoms appeared suddenly (on average 18 years after the first dopa-responsive dystonia symptoms) and were unresponsive to L-Dopa. These patients showed significantly higher disability and received unnecessary treatments.

Conclusion

Functional neurological movement disorders are common in patients with dopa-responsive dystonia and impact the clinical picture and the degree of disability. Diagnosing both disorders in an individual patient has substantial therapeutical implications because increases in L-Dopa dosages to treat functional symptoms should be avoided, and physiotherapy should relocate attention away from the affected body region so that movements in the affected body part can be executed without external control to facilitates automatic movements. Physiotherapy should be complemented by psychoeducation and psychotherapeutic approaches.
{"title":"Functional movement disorders in dopa-responsive dystonia","authors":"Feline Hamami ,&nbsp;Jannik Prasuhn ,&nbsp;Leon-Claas van Well ,&nbsp;Katja Lohmann ,&nbsp;Christine Klein ,&nbsp;Norbert Brüggemann ,&nbsp;Tobias Bäumer ,&nbsp;Alexander Münchau ,&nbsp;Anne Weissbach","doi":"10.1016/j.parkreldis.2025.107292","DOIUrl":"10.1016/j.parkreldis.2025.107292","url":null,"abstract":"<div><h3>Background</h3><div>Functional neurological movement disorders are common and disabling. Little is known about their coexistence with other non-functional movement disorders and their impact on the general disease burden.</div></div><div><h3>Objectives</h3><div>Investigating frequency and characteristics of functional movement disorders in <em>GCH1</em>-positive dopa-responsive dystonia patients.</div></div><div><h3>Methods</h3><div>Twenty-one patients underwent a detailed clinical motor examination and completed self-questionnaires evaluating non-motor characteristics.</div></div><div><h3>Results</h3><div>Seven patients (33 %) had comorbid functional movement symptoms, including functional gait disorders (n = 7), balance disturbances (n = 7), and weakness (n = 5), dominating the clinical phenotype and resulting in disability with immobilization. None of them was previously diagnosed with or treated for the functional symptoms. Functional movement symptoms appeared suddenly (on average 18 years after the first dopa-responsive dystonia symptoms) and were unresponsive to L-Dopa. These patients showed significantly higher disability and received unnecessary treatments.</div></div><div><h3>Conclusion</h3><div>Functional neurological movement disorders are common in patients with dopa-responsive dystonia and impact the clinical picture and the degree of disability. Diagnosing both disorders in an individual patient has substantial therapeutical implications because increases in L-Dopa dosages to treat functional symptoms should be avoided, and physiotherapy should relocate attention away from the affected body region so that movements in the affected body part can be executed without external control to facilitates automatic movements. Physiotherapy should be complemented by psychoeducation and psychotherapeutic approaches.</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"132 ","pages":"Article 107292"},"PeriodicalIF":3.1,"publicationDate":"2025-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143029238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reassessing the hypothesis of essential tremor as a prodromal feature of Parkinson's disease. 重新评估原发性震颤作为帕金森病前驱特征的假设。
IF 3.1 3区 医学 Q2 CLINICAL NEUROLOGY
Parkinsonism & related disorders
Pub Date : 2025-01-17 DOI: 10.1016/j.parkreldis.2025.107268
Qiu-Han Xu, Jia-Li Wang, Yi-Ling Wang, Bao-Rong Zhang, Jun Tian
{"title":"Reassessing the hypothesis of essential tremor as a prodromal feature of Parkinson's disease.","authors":"Qiu-Han Xu, Jia-Li Wang, Yi-Ling Wang, Bao-Rong Zhang, Jun Tian","doi":"10.1016/j.parkreldis.2025.107268","DOIUrl":"https://doi.org/10.1016/j.parkreldis.2025.107268","url":null,"abstract":"","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":" ","pages":"107268"},"PeriodicalIF":3.1,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143009621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring the neuroprotective potential of immunosuppressants in Parkinson's disease
IF 3.1 3区 医学 Q2 CLINICAL NEUROLOGY
Parkinsonism & related disorders
Pub Date : 2025-01-16 DOI: 10.1016/j.parkreldis.2025.107294
Huiam M. Mubarak , Brad A. Racette , Jordan A. Killion , Irene M. Faust , Osvaldo J. Laurido-Soto , Sai Anmisha Doddamreddy , Susan Searles Nielsen

Introduction

Neuroprotective therapy to slow Parkinson's disease (PD) progression is a critical unmet need. Neuroinflammation likely represents an important pathophysiologic mechanism for disease progression. Medications that target this inflammation, such as immunosuppressants, represent potential disease-modifying therapies for PD. The relation between these medications and PD risk might inform candidate selection.

Methods

We conducted a population-based case-control study using Medicare data from the United States. The study included 207,532 incident PD cases and 975,177 controls from 2016 to 2018, age 67–110. We examined the association between PD risk and immunosuppressant use before PD diagnosis/control selection. We considered 37 immunosuppressants, representing >10 medication classes, in Part D prescription claims. We used logistic regression to estimate the relative risk (RR) and 95 % confidence interval (CI) between each medication and PD, while accounting for age, sex, race/ethnicity, smoking, and healthcare utilization. In sensitivity analyses we applied exposure lagging, restricted to immunosuppressant users, and corrected for multiple comparisons.

Results

Medicare beneficiaries using the calcineurin inhibitor tacrolimus (RR 0.49, CI 0.40–0.60) and mTOR inhibitors everolimus (RR 0.38, CI 0.26–0.56) and sirolimus (RR 0.59, CI 0.37–0.93) had a lower risk of PD compared to those not taking the medication. The TNF inhibitor certolizumab was also associated with lower PD risk (RR 0.54, CI 0.34–0.84). Tacrolimus and everolimus remained significant after Bonferroni correction. Sensitivity analyses otherwise confirmed results for all four medications.

Conclusion

Calcineurin or mTOR inhibition might reduce PD risk. Future studies should examine whether these medications or structurally similar agents might have potential as disease-modifying therapies for PD.
{"title":"Exploring the neuroprotective potential of immunosuppressants in Parkinson's disease","authors":"Huiam M. Mubarak ,&nbsp;Brad A. Racette ,&nbsp;Jordan A. Killion ,&nbsp;Irene M. Faust ,&nbsp;Osvaldo J. Laurido-Soto ,&nbsp;Sai Anmisha Doddamreddy ,&nbsp;Susan Searles Nielsen","doi":"10.1016/j.parkreldis.2025.107294","DOIUrl":"10.1016/j.parkreldis.2025.107294","url":null,"abstract":"<div><h3>Introduction</h3><div>Neuroprotective therapy to slow Parkinson's disease (PD) progression is a critical unmet need. Neuroinflammation likely represents an important pathophysiologic mechanism for disease progression. Medications that target this inflammation, such as immunosuppressants, represent potential disease-modifying therapies for PD. The relation between these medications and PD risk might inform candidate selection.</div></div><div><h3>Methods</h3><div>We conducted a population-based case-control study using Medicare data from the United States. The study included 207,532 incident PD cases and 975,177 controls from 2016 to 2018, age 67–110. We examined the association between PD risk and immunosuppressant use before PD diagnosis/control selection. We considered 37 immunosuppressants, representing &gt;10 medication classes, in Part D prescription claims. We used logistic regression to estimate the relative risk (RR) and 95 % confidence interval (CI) between each medication and PD, while accounting for age, sex, race/ethnicity, smoking, and healthcare utilization. In sensitivity analyses we applied exposure lagging, restricted to immunosuppressant users, and corrected for multiple comparisons.</div></div><div><h3>Results</h3><div>Medicare beneficiaries using the calcineurin inhibitor tacrolimus (RR 0.49, CI 0.40–0.60) and mTOR inhibitors everolimus (RR 0.38, CI 0.26–0.56) and sirolimus (RR 0.59, CI 0.37–0.93) had a lower risk of PD compared to those not taking the medication. The TNF inhibitor certolizumab was also associated with lower PD risk (RR 0.54, CI 0.34–0.84). Tacrolimus and everolimus remained significant after Bonferroni correction. Sensitivity analyses otherwise confirmed results for all four medications.</div></div><div><h3>Conclusion</h3><div>Calcineurin or mTOR inhibition might reduce PD risk. Future studies should examine whether these medications or structurally similar agents might have potential as disease-modifying therapies for PD.</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"132 ","pages":"Article 107294"},"PeriodicalIF":3.1,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143060094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Audible tremor: Analysis of the validity of audible information in assessing tremor severity 可听震颤：可听信息评估震颤严重程度的有效性分析。
IF 3.1 3区 医学 Q2 CLINICAL NEUROLOGY
Parkinsonism & related disorders
Pub Date : 2025-01-16 DOI: 10.1016/j.parkreldis.2025.107291
Natalie Grill , Ethan Wainman , Vibhash D. Sharma , Padraig O'Suilleabhain , Elan D. Louis

Introduction

Assessing the severity of kinetic tremor is important in clinical and research settings. Archimedes spirals are often used to assess tremor severity. Rating tremor from spirals has been based solely on visual information. However, one can often “hear” tremor.

Objectives

We evaluated the type of information that could be gained from hearing tremors and assessed its validity using visualized tremor as a gold standard.

Methods

52 essential tremor cases (94 spirals), 11 Parkinson's disease patients and 11 controls (20 spirals each) were enrolled. During videotaping, cases drew Archimedes spirals in a standardized manner. Three experienced movement disorders neurologists first listened to videotaped spiral drawing (no visual) and assigned a tremor severity rating using Washington Heights Inwood Genetic Study of Essential Tremor (WHIGET) ratings (0, 0.5, 1, 1.5, 2, 3). Later, the neurologist rated the physical (i.e., visual) spiral and assigned a WHIGET tremor rating.

Results

The Spearman's correlation coefficient (visual vs. auditory rating) was 0.721 (p < 0.001) and the weighted kappa statistic was 0.674, a level of agreement that is considered good.

Conclusions

Auditory information provides in-time synchronous corroboration of what the rater is seeing. That is, it informs the visual data and provides construct validity. The results of this study have ramifications for observational and experimental therapeutic studies, which commonly rely on videotaped tremor examinations. Additional corroborative information is available if the sound is left on. Regardless of the decision to present sound to the rater or not, clear instructions and a standardized practice within the study are imperative.
在临床和研究中，评估动态性震颤的严重程度是很重要的。阿基米德螺旋常用于评估震颤的严重程度。从螺旋中评估震颤完全是基于视觉信息。然而，人们经常可以“听到”震颤。目的：我们评估了从听觉震颤中获得的信息类型，并以视觉震颤作为金标准评估了其有效性。方法：选取特发性震颤患者52例（94个螺旋），帕金森病患者11例，对照组11例（各20个螺旋）。在录像过程中，凯斯以标准化的方式画出了阿基米德螺旋。三位经验丰富的运动障碍神经科医生首先听了录像的螺旋图（无视觉），并使用华盛顿高地因伍德原发性震颤遗传研究（WHIGET）评级（0,0.5,1,1.5,2,3）分配震颤严重程度评级。随后，神经科医生对物理（即视觉）螺旋进行评级，并分配WHIGET震颤评级。结果：斯皮尔曼相关系数（视觉与听觉评分）为0.721 (p)。结论：听觉信息为评分者所看到的提供了及时的同步佐证。也就是说，它告知可视化数据并提供构造有效性。这项研究的结果对观察性和实验性治疗性研究有影响，这些研究通常依赖于录像震颤检查。如果声音一直开着，可以获得额外的确证信息。无论是否决定向评分者提供声音，在研究中明确的指示和标准化的做法都是必不可少的。
{"title":"Audible tremor: Analysis of the validity of audible information in assessing tremor severity","authors":"Natalie Grill ,&nbsp;Ethan Wainman ,&nbsp;Vibhash D. Sharma ,&nbsp;Padraig O'Suilleabhain ,&nbsp;Elan D. Louis","doi":"10.1016/j.parkreldis.2025.107291","DOIUrl":"10.1016/j.parkreldis.2025.107291","url":null,"abstract":"<div><h3>Introduction</h3><div>Assessing the severity of kinetic tremor is important in clinical and research settings. Archimedes spirals are often used to assess tremor severity. Rating tremor from spirals has been based solely on visual information. However, one can often “hear” tremor.</div></div><div><h3>Objectives</h3><div>We evaluated the type of information that could be gained from hearing tremors and assessed its validity using visualized tremor as a gold standard.</div></div><div><h3>Methods</h3><div>52 essential tremor cases (94 spirals), 11 Parkinson's disease patients and 11 controls (20 spirals each) were enrolled. During videotaping, cases drew Archimedes spirals in a standardized manner. Three experienced movement disorders neurologists first listened to videotaped spiral drawing (no visual) and assigned a tremor severity rating using Washington Heights Inwood Genetic Study of Essential Tremor (WHIGET) ratings (0, 0.5, 1, 1.5, 2, 3). Later, the neurologist rated the physical (i.e., visual) spiral and assigned a WHIGET tremor rating.</div></div><div><h3>Results</h3><div>The Spearman's correlation coefficient (visual vs. auditory rating) was 0.721 (p &lt; 0.001) and the weighted kappa statistic was 0.674, a level of agreement that is considered good.</div></div><div><h3>Conclusions</h3><div>Auditory information provides <em>in-time synchronous corroboration</em> of what the rater is seeing. That is, it informs the visual data and provides construct validity. The results of this study have ramifications for observational and experimental therapeutic studies, which commonly rely on videotaped tremor examinations. Additional corroborative information is available if the sound is left on. Regardless of the decision to present sound to the rater or not, clear instructions and a standardized practice within the study are imperative.</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"132 ","pages":"Article 107291"},"PeriodicalIF":3.1,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143009637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vibro-tactile stimulation of the neck induces head righting in people with cervical dystonia
IF 3.1 3区 医学 Q2 CLINICAL NEUROLOGY
Parkinsonism & related disorders
Pub Date : 2025-01-16 DOI: 10.1016/j.parkreldis.2025.107263
Laura Avanzino , Jiapeng Xu , Davide Martino , Antonella Conte , Stephanie Standal , Parisa Salehi , Sara Terranova , Gaia Bonassi , Parisa Alizadeh , Janet Adesewa Adeoti , Daniele Belvisi , Matteo Costanzo , Jinseok Oh , Jürgen Konczak

Introduction

Cervical dystonia (CD) is characterized by involuntary neck muscle spasms that lead to abnormal head movements or postures. It is associated with somatosensory (tactile and proprioceptive) dysfunction. Here we tested whether vibro-tactile stimulation (VTS) of the cervical muscles constitutes a non-invasive form of neuromodulation of the somatosensory system that can provide temporary symptom relief for people with CD.

Material and method

In a multi-centre study, 67 CD patients (44 female) received VTS to sternocleidomastoid and/or trapezius muscles for up to 45 min under 9 different stimulation conditions. Retention was assessed 1, 5 and 20 min past VTS. Head angles and neck muscle EMG were recorded. The primary outcome measure was a head angle index (HAI), a composite measure reflecting the head deviation across the three axes of the head.

Results

After identifying the most effective VTS condition for each participant, analysis showed that 85 % (57/67) of participants experienced an improvement in HAI of at least 10 % during the application of VTS. HAI improved by 50 % or higher in 26/67 of participants. For those responding to VTS, the effects tended to decay within 20 min. For the different CD phenotypes several stimulation sites could induce similarly large relative improvements in head posture.

Conclusion

The study provides first systematic evidence that cervical VTS can induce fast-acting improvements in abnormal head posture in patients with CD. It demonstrates that a stimulation of somatosensory afferent networks modulates the innervation of dystonic muscles. It highlights the potential of cervical VTS as an adjuvant, non-invasive neuromodulation treatment in CD.
{"title":"Vibro-tactile stimulation of the neck induces head righting in people with cervical dystonia","authors":"Laura Avanzino ,&nbsp;Jiapeng Xu ,&nbsp;Davide Martino ,&nbsp;Antonella Conte ,&nbsp;Stephanie Standal ,&nbsp;Parisa Salehi ,&nbsp;Sara Terranova ,&nbsp;Gaia Bonassi ,&nbsp;Parisa Alizadeh ,&nbsp;Janet Adesewa Adeoti ,&nbsp;Daniele Belvisi ,&nbsp;Matteo Costanzo ,&nbsp;Jinseok Oh ,&nbsp;Jürgen Konczak","doi":"10.1016/j.parkreldis.2025.107263","DOIUrl":"10.1016/j.parkreldis.2025.107263","url":null,"abstract":"<div><h3>Introduction</h3><div>Cervical dystonia (CD) is characterized by involuntary neck muscle spasms that lead to abnormal head movements or postures. It is associated with somatosensory (tactile and proprioceptive) dysfunction. Here we tested whether vibro-tactile stimulation (VTS) of the cervical muscles constitutes a non-invasive form of neuromodulation of the somatosensory system that can provide temporary symptom relief for people with CD.</div></div><div><h3>Material and method</h3><div>In a multi-centre study, 67 CD patients (44 female) received VTS to sternocleidomastoid and/or trapezius muscles for up to 45 min under 9 different stimulation conditions. Retention was assessed 1, 5 and 20 min past VTS. Head angles and neck muscle EMG were recorded. The primary outcome measure was a head angle index (HAI), a composite measure reflecting the head deviation across the three axes of the head.</div></div><div><h3>Results</h3><div>After identifying the most effective VTS condition for each participant, analysis showed that 85 % (57/67) of participants experienced an improvement in HAI of at least 10 % during the application of VTS. HAI improved by 50 % or higher in 26/67 of participants. For those responding to VTS, the effects tended to decay within 20 min. For the different CD phenotypes several stimulation sites could induce similarly large relative improvements in head posture.</div></div><div><h3>Conclusion</h3><div>The study provides first systematic evidence that cervical VTS can induce fast-acting improvements in abnormal head posture in patients with CD. It demonstrates that a stimulation of somatosensory afferent networks modulates the innervation of dystonic muscles. It highlights the potential of cervical VTS as an adjuvant, non-invasive neuromodulation treatment in CD.</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"132 ","pages":"Article 107263"},"PeriodicalIF":3.1,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143029245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term, continuous, subcutaneous levodopa/carbidopa infusion with ND0612 in Parkinson's disease: 3-year outcomes from the open-label BeyoND study
IF 3.1 3区 医学 Q2 CLINICAL NEUROLOGY
Parkinsonism & related disorders
Pub Date : 2025-01-16 DOI: 10.1016/j.parkreldis.2025.107293
Aaron L. Ellenbogen , Werner Poewe , Alberto J. Espay , Tanya Simuni , Tanya Gurevich , Tami Yardeni , Nelson Lopes , Nissim Sasson , Ryan Case , Fabrizio Stocchi

Introduction

ND0612 is being investigated as a continuous, subcutaneous levodopa/carbidopa infusion, in combination with oral levodopa/carbidopa, for motor fluctuations in Parkinson's disease (PD). One-year data from the ongoing BeyoND study (NCT02726386) showed that the ND0612 regimen was safe and well tolerated and provided a sustained ≥2-h improvement in daily Good ON-time through 12 months of treatment.

Methods

We describe 3-year safety and efficacy outcomes for participants who completed 12 months of ND0612 treatment in the core study period and entered the extension phase.

Results

Of the 214 enrolled participants, 120 completed the core 1-year period, and 114 participants continued into the extension phase. Of these, 95/114 (83.3 %) completed 2 years and 77/114 (67.5 %) completed 3 years of study treatment. Key reasons for discontinuation were treatment-emergent adverse events (TEAEs) (n = 5 and n = 11 after 2 and 3 years, respectively) and withdrawal of consent (n = 9 and n = 5, respectively). TEAEs were reported by 105/114 (92.1 %) participants in Year 1, 77/114 (67.5 %) in Year 2, and 73/95 (76.8 %) in Year 3. While most participants experienced infusion site reactions, these led to discontinuation in only five participants during this extension. At Month 36, the mean reduction in OFF-time from baseline was 2.81 h and the increase in Good ON-time was 2.79 h.

Conclusions

Three-year results from this open-label study support the long-term safety, tolerability, and efficacy of ND0612. For participants who entered the extension phase, the high rate of retention supports a favorable benefit-risk ratio of the ND0612 regimen for patients with PD experiencing motor fluctuations.
{"title":"Long-term, continuous, subcutaneous levodopa/carbidopa infusion with ND0612 in Parkinson's disease: 3-year outcomes from the open-label BeyoND study","authors":"Aaron L. Ellenbogen ,&nbsp;Werner Poewe ,&nbsp;Alberto J. Espay ,&nbsp;Tanya Simuni ,&nbsp;Tanya Gurevich ,&nbsp;Tami Yardeni ,&nbsp;Nelson Lopes ,&nbsp;Nissim Sasson ,&nbsp;Ryan Case ,&nbsp;Fabrizio Stocchi","doi":"10.1016/j.parkreldis.2025.107293","DOIUrl":"10.1016/j.parkreldis.2025.107293","url":null,"abstract":"<div><h3>Introduction</h3><div>ND0612 is being investigated as a continuous, subcutaneous levodopa/carbidopa infusion, in combination with oral levodopa/carbidopa, for motor fluctuations in Parkinson's disease (PD). One-year data from the ongoing BeyoND study (NCT02726386) showed that the ND0612 regimen was safe and well tolerated and provided a sustained ≥2-h improvement in daily Good ON-time through 12 months of treatment.</div></div><div><h3>Methods</h3><div>We describe 3-year safety and efficacy outcomes for participants who completed 12 months of ND0612 treatment in the core study period and entered the extension phase.</div></div><div><h3>Results</h3><div>Of the 214 enrolled participants, 120 completed the core 1-year period, and 114 participants continued into the extension phase. Of these, 95/114 (83.3 %) completed 2 years and 77/114 (67.5 %) completed 3 years of study treatment. Key reasons for discontinuation were treatment-emergent adverse events (TEAEs) (n = 5 and n = 11 after 2 and 3 years, respectively) and withdrawal of consent (n = 9 and n = 5, respectively). TEAEs were reported by 105/114 (92.1 %) participants in Year 1, 77/114 (67.5 %) in Year 2, and 73/95 (76.8 %) in Year 3. While most participants experienced infusion site reactions, these led to discontinuation in only five participants during this extension. At Month 36, the mean reduction in OFF-time from baseline was 2.81 h and the increase in Good ON-time was 2.79 h.</div></div><div><h3>Conclusions</h3><div>Three-year results from this open-label study support the long-term safety, tolerability, and efficacy of ND0612. For participants who entered the extension phase, the high rate of retention supports a favorable benefit-risk ratio of the ND0612 regimen for patients with PD experiencing motor fluctuations.</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"132 ","pages":"Article 107293"},"PeriodicalIF":3.1,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143067165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unveiling distinct clinical manifestations of primary familial brain calcifications in Asian and European patients: A study based on 10-year individual-level data 揭示亚洲和欧洲患者原发性家族性脑钙化的独特临床表现：一项基于10年个体水平数据的研究。
IF 3.1 3区 医学 Q2 CLINICAL NEUROLOGY
Parkinsonism & related disorders
Pub Date : 2025-01-16 DOI: 10.1016/j.parkreldis.2025.107290
Dehao Yang , Honghao Huang , Tian Zeng , Lebo Wang , Chenxin Ying , Xinhui Chen , Xinbo Zhou , Fangyue Sun , Yilin Chen , Shengqi Li , Bo Wang , Sheng Wu , Fei Xie , Zhidong Cen , Wei Luo

Background

Primary Familial Brain Calcification (PFBC) can manifest clinically with a complex and heterogeneous array of symptoms, including parkinsonism, dysarthria, and cognitive impairment. However, the distinct presentations of PFBC in Asian and European populations remain unclear.

Methods

We conducted a systematic search of PubMed for studies involving genetically confirmed PFBC patients. Demographic data, genetic information, radiological examinations, and clinical characteristics were extracted for each case.

Results

The study included 120 publications and 564 genetically confirmed PFBC patients. Asian and European PFBC populations represented 54 % and 37 % of global patients, respectively. While calcification patterns showed no significant differences between Asian and European PFBC patients, European autosomal dominant PFBC variant carriers were more likely to exhibit clinical symptoms compared to their Asian counterparts (OR = 2.90, 95 % CI 1.55–5.60) and had an earlier estimated age of onset (median age 42 vs 58).

Conclusion

The interaction between regional differences and genetically determined calcification severity may collectively influence PFBC symptom progression. Future research should further explore the potential roles of gene modifiers, ethnic background, socioeconomic and environmental exposure factors underlying regional differences in PFBC progression.
背景：原发性家族性脑钙化（PFBC）在临床上表现为一系列复杂且异质性的症状，包括帕金森症、构音障碍和认知障碍。然而，PFBC在亚洲和欧洲人群中的不同表现仍不清楚。方法：我们对PubMed中涉及基因证实的PFBC患者的研究进行了系统检索。提取每个病例的人口统计资料、遗传信息、放射学检查和临床特征。结果：该研究包括120篇出版物和564例基因证实的PFBC患者。亚洲和欧洲PFBC人群分别占全球患者的54%和37%。虽然钙化模式在亚洲和欧洲PFBC患者之间没有显着差异，但与亚洲患者相比，欧洲常染色体显性PFBC变异携带者更有可能表现出临床症状（OR = 2.90, 95% CI 1.55-5.60），并且估计发病年龄更早（中位年龄42岁对58岁）。结论：区域差异和基因决定的钙化严重程度之间的相互作用可能共同影响PFBC症状的进展。未来的研究应进一步探讨基因修饰剂、种族背景、社会经济和环境暴露因素在PFBC进展地区差异中的潜在作用。
{"title":"Unveiling distinct clinical manifestations of primary familial brain calcifications in Asian and European patients: A study based on 10-year individual-level data","authors":"Dehao Yang ,&nbsp;Honghao Huang ,&nbsp;Tian Zeng ,&nbsp;Lebo Wang ,&nbsp;Chenxin Ying ,&nbsp;Xinhui Chen ,&nbsp;Xinbo Zhou ,&nbsp;Fangyue Sun ,&nbsp;Yilin Chen ,&nbsp;Shengqi Li ,&nbsp;Bo Wang ,&nbsp;Sheng Wu ,&nbsp;Fei Xie ,&nbsp;Zhidong Cen ,&nbsp;Wei Luo","doi":"10.1016/j.parkreldis.2025.107290","DOIUrl":"10.1016/j.parkreldis.2025.107290","url":null,"abstract":"<div><h3>Background</h3><div>Primary Familial Brain Calcification (PFBC) can manifest clinically with a complex and heterogeneous array of symptoms, including parkinsonism, dysarthria, and cognitive impairment. However, the distinct presentations of PFBC in Asian and European populations remain unclear.</div></div><div><h3>Methods</h3><div>We conducted a systematic search of PubMed for studies involving genetically confirmed PFBC patients. Demographic data, genetic information, radiological examinations, and clinical characteristics were extracted for each case.</div></div><div><h3>Results</h3><div>The study included 120 publications and 564 genetically confirmed PFBC patients. Asian and European PFBC populations represented 54 % and 37 % of global patients, respectively. While calcification patterns showed no significant differences between Asian and European PFBC patients, European autosomal dominant PFBC variant carriers were more likely to exhibit clinical symptoms compared to their Asian counterparts (OR = 2.90, 95 % CI 1.55–5.60) and had an earlier estimated age of onset (median age 42 vs 58).</div></div><div><h3>Conclusion</h3><div>The interaction between regional differences and genetically determined calcification severity may collectively influence PFBC symptom progression. Future research should further explore the potential roles of gene modifiers, ethnic background, socioeconomic and environmental exposure factors underlying regional differences in PFBC progression.</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"132 ","pages":"Article 107290"},"PeriodicalIF":3.1,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143009718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Frequency of anti-IgLON5 disease in patients with a typical clinical presentation of progressive supranuclear palsy/corticobasal syndrome.
IF 3.1 3区 医学 Q2 CLINICAL NEUROLOGY
Parkinsonism & related disorders
Pub Date : 2025-01-15 DOI: 10.1016/j.parkreldis.2025.107289
Yoya Ono, Hiroshi Takigawa, Akira Takekoshi, Nobuaki Yoshikura, Ikuko Aiba, Ritsuko Hanajima, Hisanori Kowa, Masato Kanazawa, Takahiko Tokuda, Aya Midori Tokumaru, Mitsuya Morita, Kazuko Hasegawa, Kenji Nakashima, Takeshi Ikeuchi, Akio Kimura, Takayoshi Shimohata

Serum anti-IgLON5 antibodies, which were tested in 223 patients meeting the diagnostic criteria for progressive supranuclear palsy/corticobasal syndrome (PSP/CBS), were negative in all patients. Our study suggests that the frequency of anti-IgLON5 disease is extremely rare in patients with typical presentation of PSP/CBS.

{"title":"Frequency of anti-IgLON5 disease in patients with a typical clinical presentation of progressive supranuclear palsy/corticobasal syndrome.","authors":"Yoya Ono, Hiroshi Takigawa, Akira Takekoshi, Nobuaki Yoshikura, Ikuko Aiba, Ritsuko Hanajima, Hisanori Kowa, Masato Kanazawa, Takahiko Tokuda, Aya Midori Tokumaru, Mitsuya Morita, Kazuko Hasegawa, Kenji Nakashima, Takeshi Ikeuchi, Akio Kimura, Takayoshi Shimohata","doi":"10.1016/j.parkreldis.2025.107289","DOIUrl":"https://doi.org/10.1016/j.parkreldis.2025.107289","url":null,"abstract":"<p><p>Serum anti-IgLON5 antibodies, which were tested in 223 patients meeting the diagnostic criteria for progressive supranuclear palsy/corticobasal syndrome (PSP/CBS), were negative in all patients. Our study suggests that the frequency of anti-IgLON5 disease is extremely rare in patients with typical presentation of PSP/CBS.</p>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":" ","pages":"107289"},"PeriodicalIF":3.1,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143024383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cropland associated with risk of Parkinson's disease in the northern Great Plains
IF 3.1 3区 医学 Q2 CLINICAL NEUROLOGY
Parkinsonism & related disorders
Pub Date : 2025-01-14 DOI: 10.1016/j.parkreldis.2025.107288
Brittany Krzyzanowski , Kassu M. Beyene , Susan Searles Nielsen , Jordan A. Killion , Brad A. Racette

Introduction

We sought to identify regional associations between cropland density and crop types and PD in the U.S.

Methods

We conducted a population-based study of 21,639,190 Medicare beneficiaries, 89,790 with incident PD in 2009. We used county-level geographic weighted regression (GWR) to identify region(s) of the U.S. where the association between PD RR and cropland density was strongest. In a broad region identified by GWR in which cropland density was associated with PD, we performed logistic regression using individual-level beneficiary data (2733 cases and 805,984 non-cases) with high-resolution cropland density data. We adjusted for age, sex, race, smoking, healthcare utilization, and PM2.5 (particulate matter <2.5 μm). We then explored PD-cropland associations for each type of crop within a subregion, in which the association was the strongest.

Results

GWR identified a 9-state region in the Great Plains in which county-level cropland density and PD RR were associated. Within this region, the strongest GWR coefficients centered around the Williston Basin. High-resolution analysis demonstrated an association between cropland density within a 5-mile radius of residential zip+4 and PD. When comparing the highest to lowest quartile of cropland density, the odds ratio (OR) for PD was 1.14 (95 % confidence interval [CI] 1.01–1.27) in the 9-state region and 1.99 (95 % CI 1.09–3.61) in the Williston Basin. In the Williston Basin, percentage of sunflowers, winter wheat, and alfalfa within 5 miles of a beneficiary's zip+4 was associated with PD.

Conclusion

We identified a region-specific association between cropland and crop type and PD in the Williston Basin.
{"title":"Cropland associated with risk of Parkinson's disease in the northern Great Plains","authors":"Brittany Krzyzanowski ,&nbsp;Kassu M. Beyene ,&nbsp;Susan Searles Nielsen ,&nbsp;Jordan A. Killion ,&nbsp;Brad A. Racette","doi":"10.1016/j.parkreldis.2025.107288","DOIUrl":"10.1016/j.parkreldis.2025.107288","url":null,"abstract":"<div><h3>Introduction</h3><div>We sought to identify regional associations between cropland density and crop types and PD in the U.S.</div></div><div><h3>Methods</h3><div>We conducted a population-based study of 21,639,190 Medicare beneficiaries, 89,790 with incident PD in 2009. We used county-level geographic weighted regression (GWR) to identify region(s) of the U.S. where the association between PD RR and cropland density was strongest. In a broad region identified by GWR in which cropland density was associated with PD, we performed logistic regression using individual-level beneficiary data (2733 cases and 805,984 non-cases) with high-resolution cropland density data. We adjusted for age, sex, race, smoking, healthcare utilization, and PM<sub>2.5</sub> (particulate matter &lt;2.5 μm). We then explored PD-cropland associations for <em>each type</em> of crop within a subregion, in which the association was the strongest.</div></div><div><h3>Results</h3><div>GWR identified a 9-state region in the Great Plains in which county-level cropland density and PD RR were associated. Within this region, the strongest GWR coefficients centered around the Williston Basin. High-resolution analysis demonstrated an association between cropland density within a 5-mile radius of residential zip+4 and PD. When comparing the highest to lowest quartile of cropland density, the odds ratio (OR) for PD was 1.14 (95 % confidence interval [CI] 1.01–1.27) in the 9-state region and 1.99 (95 % CI 1.09–3.61) in the Williston Basin. In the Williston Basin, percentage of sunflowers, winter wheat, and alfalfa within 5 miles of a beneficiary's zip+4 was associated with PD.</div></div><div><h3>Conclusion</h3><div>We identified a region-specific association between cropland and crop type and PD in the Williston Basin.</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"132 ","pages":"Article 107288"},"PeriodicalIF":3.1,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143040991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Case report -Cavernoma involving substantia nigra and nigrostriatal pathway as a rare cause of secondary parkinsonism with a 5 year follow up 病例报告-累及黑质和黑质纹状体通路的海绵状瘤是继发性帕金森病的罕见病因，随访5年。
IF 3.1 3区 医学 Q2 CLINICAL NEUROLOGY
Parkinsonism & related disorders
Pub Date : 2025-01-13 DOI: 10.1016/j.parkreldis.2025.107281
Sahana Sathyanarayana , Jacopo Pasquini , David Ledingham , Dipayan Mitra , Naomi Warren , Nicola Pavese
{"title":"Case report -Cavernoma involving substantia nigra and nigrostriatal pathway as a rare cause of secondary parkinsonism with a 5 year follow up","authors":"Sahana Sathyanarayana ,&nbsp;Jacopo Pasquini ,&nbsp;David Ledingham ,&nbsp;Dipayan Mitra ,&nbsp;Naomi Warren ,&nbsp;Nicola Pavese","doi":"10.1016/j.parkreldis.2025.107281","DOIUrl":"10.1016/j.parkreldis.2025.107281","url":null,"abstract":"","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"132 ","pages":"Article 107281"},"PeriodicalIF":3.1,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143009643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
类型
全部 化学•材料 生命科学 医学 物理 工程技术 环境•农林 材料科学 地球科学 法学 管理学 化学 环境科学与生态学 计算机科学 教育学 经济学 农林科学 人文科学 生物学 数学 物理与天体物理 心理学 综合性期刊 其他 工业工程 理学 历史学 农学 文学 信息工程
数据库
全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley
期刊
Parkinsonism & related disorders
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
﹀
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们：info@booksci.cn
Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1